Century Financial Statements From 2010 to 2025

IPSC Stock  USD 0.59  0.04  6.35%   
Century Therapeutics financial statements provide useful quarterly and yearly information to potential Century Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Century Therapeutics financial statements helps investors assess Century Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Century Therapeutics' valuation are summarized below:
Gross Profit
-97.5 M
Market Capitalization
53.2 M
Enterprise Value Revenue
1.9555
Revenue
2.7 M
Earnings Share
(1.83)
We have found one hundred twenty available fundamental signals for Century Therapeutics, which can be analyzed and compared to other ratios and to its rivals. Investors should ensure to validate all of Century Therapeutics' prevailing performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. As of March 19, 2025, Market Cap is expected to decline to about 215.1 M. In addition to that, Enterprise Value is expected to decline to about 216.1 M

Century Therapeutics Total Revenue

1.91 Million

Check Century Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Century Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 518.7 K, Selling General Administrative of 33.3 M or Total Revenue of 1.9 M, as well as many indicators such as Price To Sales Ratio of 58.04, Dividend Yield of 0.0 or PTB Ratio of 1.01. Century financial statements analysis is a perfect complement when working with Century Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Century Therapeutics Correlation against competitors.
For information on how to trade Century Stock refer to our How to Trade Century Stock guide.

Century Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets352.6 M324.6 M510.5 M
Slightly volatile
Other Current Liabilities7.9 M8.3 M60 M
Slightly volatile
Total Current Liabilities15.3 M16.1 M144.4 M
Slightly volatile
Other Liabilities134.7 M128.3 M35.9 M
Slightly volatile
Accounts Payable2.3 M2.5 M21.7 M
Slightly volatile
Cash44.2 M54.4 M29.3 M
Slightly volatile
Other Assets0.860.9M
Slightly volatile
Long Term Debt3.2 M3.4 M79.7 M
Slightly volatile
Other Current AssetsM4.9 M3.7 M
Pretty Stable
Total Liabilities212.3 M158.3 M313.7 M
Slightly volatile
Intangible Assets16.6 M8.5 M20.6 M
Slightly volatile
Property Plant Equipment134.8 M74.5 M219.5 M
Slightly volatile
Property Plant And Equipment Net64.1 M105.9 M30.2 M
Slightly volatile
Non Current Assets Total130.8 M211.3 M62.3 M
Slightly volatile
Non Currrent Assets Other2.4 M2.9 M1.1 M
Slightly volatile
Cash And Short Term Investments191 M198.6 M124.5 M
Slightly volatile
Net Receivables599.7 K764.8 K324.8 K
Slightly volatile
Common Stock Total Equity3.6 K6.9 K2.4 K
Slightly volatile
Common Stock Shares Outstanding62 M68.2 M56.6 M
Slightly volatile
Short Term Investments134 M144.2 M76.5 M
Slightly volatile
Liabilities And Stockholders Equity326.1 M414.8 M190.1 M
Slightly volatile
Non Current Liabilities Total114.9 M142.3 M162.1 M
Slightly volatile
Long Term Investments62 M102.5 M30.2 M
Slightly volatile
Property Plant And Equipment Gross138.8 M132.2 M35.4 M
Slightly volatile
Total Current Assets195.3 M203.5 M127.7 M
Slightly volatile
Capital Stock4.2 K6.9 K2.4 K
Slightly volatile
Net Working Capital178.1 M183 M118.8 M
Slightly volatile
Common Stock4.2 K6.9 K2.4 K
Slightly volatile
Short and Long Term Debt Total39.2 M55.4 M28.3 M
Slightly volatile
Current Deferred Revenue5.7 MM4.3 M
Slightly volatile
Short Term Debt2.9 M1.7 M1.1 M
Slightly volatile
Capital Surpluse885.1 M947.9 M806.4 M
Slightly volatile
Short and Long Term Debt4.1 M7.5 M2.3 M
Slightly volatile
Non Current Liabilities Other47.9 K50.4 K1.6 M
Slightly volatile

Century Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative33.3 M31.2 M57 M
Slightly volatile
Research Development55 M106.6 M37.3 M
Slightly volatile
Cost Of Revenue11.2 M11.7 M365.9 M
Slightly volatile
Depreciation And Amortization11.2 M11.7 M145.4 M
Slightly volatile
Other Operating Expenses99.4 M171.1 M56.4 M
Slightly volatile
Total Operating Expenses99.4 M171.1 M56.4 M
Slightly volatile
Reconciled Depreciation14.9 M14.2 M3.6 M
Slightly volatile
Income Tax Expense2.3 M2.2 M1.2 M
Pretty Stable
Tax Provision3.4 M3.2 M621.7 K
Slightly volatile
Interest Income9.4 M14.6 M5.9 M
Slightly volatile
Non RecurringMM9.8 M
Slightly volatile
Selling And Marketing Expenses10.4 M11.7 M12.8 M
Slightly volatile

Century Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Change To Inventory115.1 M70.5 M129.3 M
Slightly volatile
Capital Expenditures22.3 M15.8 M20.8 M
Pretty Stable
Change To Account Receivables43.9 M49.4 M53.8 M
Slightly volatile
End Period Cash Flow59.2 M56.7 M48 M
Slightly volatile
Net Borrowings7.8 M8.8 M9.6 M
Slightly volatile
Stock Based Compensation17.7 M16.8 M4.2 M
Slightly volatile
Begin Period Cash Flow54.5 M99.2 M42.8 M
Slightly volatile
Depreciation15.8 M15 M3.7 M
Slightly volatile
Other Non Cash Items9.6 M10.2 M143.4 M
Slightly volatile
Issuance Of Capital Stock826.8 K870.3 K82.4 M
Very volatile
Change To Netincome9.1 M9.6 M144.5 M
Slightly volatile
Sale Purchase Of Stock23.2 M24.4 M174.3 M
Slightly volatile
Cash And Cash Equivalents Changes23.4 M25.3 M29.4 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio58.0479.360.3944
Slightly volatile
Days Sales Outstanding43.8149.2853.7336
Slightly volatile
Stock Based Compensation To Revenue3.445.892.6594
Slightly volatile
Capex To Depreciation1.151.217.8025
Slightly volatile
EV To Sales55.5179.6454.8347
Slightly volatile
Payables Turnover4.54.281.1134
Slightly volatile
Sales General And Administrative To Revenue8.6613.987.3641
Slightly volatile
Research And Ddevelopement To Revenue24.8437.3323.2272
Slightly volatile
Capex To Revenue4.825.535.8138
Slightly volatile
Cash Per Share2.452.622.1095
Slightly volatile
Days Payables Outstanding83.7988.21.6 K
Slightly volatile
Intangibles To Total Assets0.07040.07920.0863
Slightly volatile
Current Ratio15.3611.4121.8412
Slightly volatile
Receivables Turnover5.346.06.541
Slightly volatile
Capex Per Share0.290.210.1692
Slightly volatile
Revenue Per Share0.07020.04330.0826
Slightly volatile
Interest Debt Per Share0.510.740.4873
Slightly volatile
Debt To Assets0.130.150.1743
Slightly volatile
Days Of Payables Outstanding83.7988.21.6 K
Slightly volatile
Ebt Per Ebit1.081.060.9995
Pretty Stable
Quick Ratio15.1611.4121.3323
Slightly volatile
Net Income Per E B T1.111.171.0228
Slightly volatile
Cash Ratio5.733.0510.4553
Slightly volatile
Days Of Sales Outstanding43.8149.2853.7336
Slightly volatile
Fixed Asset Turnover0.03890.02790.0435
Slightly volatile
Debt Ratio0.130.150.1743
Slightly volatile
Price Sales Ratio58.0479.360.3944
Slightly volatile
Asset Turnover0.00930.00710.0101
Slightly volatile

Century Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap215.1 M226.5 M973.5 M
Slightly volatile
Enterprise Value216.1 M227.4 M941.5 M
Slightly volatile

Century Fundamental Market Drivers

Cash And Short Term Investments172.7 M

Century Upcoming Events

21st of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Century Therapeutics Financial Statements

Century Therapeutics stakeholders use historical fundamental indicators, such as Century Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Century Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Century Therapeutics' assets and liabilities are reflected in the revenues and expenses on Century Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Century Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred RevenueM5.7 M
Total RevenueM1.9 M
Cost Of Revenue11.7 M11.2 M
Stock Based Compensation To Revenue 5.89  3.44 
Sales General And Administrative To Revenue 13.98  8.66 
Research And Ddevelopement To Revenue 37.33  24.84 
Capex To Revenue 5.53  4.82 
Revenue Per Share 0.04  0.07 
Ebit Per Revenue(75.40)(79.17)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Century Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Century Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Century Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Century Therapeutics Stock:
Check out the analysis of Century Therapeutics Correlation against competitors.
For information on how to trade Century Stock refer to our How to Trade Century Stock guide.
You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Century Therapeutics. If investors know Century will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Century Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.83)
Revenue Per Share
0.037
Quarterly Revenue Growth
4.345
Return On Assets
(0.21)
Return On Equity
(0.63)
The market value of Century Therapeutics is measured differently than its book value, which is the value of Century that is recorded on the company's balance sheet. Investors also form their own opinion of Century Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Century Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Century Therapeutics' market value can be influenced by many factors that don't directly affect Century Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Century Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Century Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Century Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.